Nuklearmedizin-nuclear Medicine最新文献_第6页

[Therapy concepts for thyroid carcinoma]. [甲状腺癌的治疗理念]。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-06-01 Epub Date: 2022-06-03 DOI: 10.1055/a-1650-9762

Friederike Eilsberger, Michael C Kreissl, Markus Luster, Andreas Pfestroff

引用次数: 0

Alpha emitting nuclides in nuclear medicine theranostics. 放射核素在核医学治疗中的应用。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-06-01 Epub Date: 2022-10-08 DOI: 10.1055/a-1650-9995

Matthias Miederer

引用次数: 1

GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals. GRPr治疗学:GRPr靶向放射性药物的成像和治疗现状。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-06-01 DOI: 10.1055/a-1759-4189

J. Kurth, Madlin Potratz, M. Heuschkel, B. Krause, S. Schwarzenböck

引用次数: 2

[Evaluation of radionuclide impurities in several radiopharmaceuticals]. [几种放射性药物中放射性核素杂质的评价]。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-04-14 DOI: 10.1055/a-1759-1815

R. Freudenberg, Lorenz Hesse, J. Kotzerke

{"title":"[Evaluation of radionuclide impurities in several radiopharmaceuticals].","authors":"R. Freudenberg, Lorenz Hesse, J. Kotzerke","doi":"10.1055/a-1759-1815","DOIUrl":"https://doi.org/10.1055/a-1759-1815","url":null,"abstract":"PURPOSE\u0000Revisions to German radiation protection laws have resulted in updated limit values, which could affect the unrestricted release of waste produced by nuclear medicine therapy. In addition, signs of long-lived concomitant nuclides in 153Sm and 223Ra radiopharmaceuticals have been seen in the past. Therefore, the goal of this article was to analyze the radionuclidic purity of selected radiopharmaceuticals.\u0000\u0000\u0000METHOD\u000048 samples from 12 different radiopharmaceuticals were examined. A high purity germanium semiconductor detector (HPGe detector) was used for the qualitative and quantitative evaluation of concomitant nuclides.\u0000\u0000\u0000RESULTS\u0000Various europium isotopes were identified in 90Y-citrate, 153Sm-Quadramet, 166Ho-QuiremSpheres, and 169Er-erbium citrate, with the greatest amount being found in 153Sm (7.0 ppm (152Eu), 8.4 ppm (154Eu), and 2.1 ppm (155Eu)). 169Yb was the most significant impurity in 169Er (513 ppm). In the case of 177Lu radiopharmaceuticals, there was a significant difference in the 177mLu content (0.8 ppm vs. 0.0024 ppm) between two different manufacturers. No concomitant nuclides could be found within the detection limits in the case of 90Y spheres, 223Ra, and 225Ac.\u0000\u0000\u0000CONCLUSION\u0000The limit values for unrestricted release are exceeded manyfold in the case of the identified concomitant nuclides. As a result, alternative release procedures (extension of the decay time, specific release, release in the individual case) or transfer to collection facilities must be considered. Technical methods for reducing or preventing impurities could also be a possible solution. Consequences for patient radiation exposure were able to be ruled out.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"37 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73773923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Oligometastatic disease in biochemical recurrence of prostate cancer: Prevalence on PSMA PET/CT and consecutive metastasis-directed therapy - Experience at a tertiary referral center. 前列腺癌生化复发中的少转移性疾病:PSMA PET/CT的患病率和连续的转移性治疗-三级转诊中心的经验

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-04-06 DOI: 10.1055/a-1697-8111

Peter J Müller, M. Dietlein, C. Kobe, A. Heidenreich, A. Drzezga

{"title":"Oligometastatic disease in biochemical recurrence of prostate cancer: Prevalence on PSMA PET/CT and consecutive metastasis-directed therapy - Experience at a tertiary referral center.","authors":"Peter J Müller, M. Dietlein, C. Kobe, A. Heidenreich, A. Drzezga","doi":"10.1055/a-1697-8111","DOIUrl":"https://doi.org/10.1055/a-1697-8111","url":null,"abstract":"AIM\u0000The aim of our study was to address the prevalence of oligometastatic recurrent prostate cancer (PCa) on PSMA-PET and the associated practice of metastasis-directed therapy (MDT). Next, we aimed to determine a PSA threshold below which most patients had local and/or oligometastatic recurrence on PSMA-PET.\u0000\u0000\u0000METHODS\u0000One hundred and ten consecutive patients with biochemical recurrence (BCR) after radical prostatectomy (RP) ± radiation were referred for 68Ga-PSMA-11 or 18F-DCFPyL PET/CT. We correlated the location and number of PSMA-positive lesions against the treatment choice after imaging. Detection rates were stratified by PSA levels at the time of PET/CT. The study design was monocentric retrospective.\u0000\u0000\u0000RESULTS\u0000Thirty-four patients (30.9%) had a PSMA-negative scan, while 17 (15.5%) had local recurrence and 59 (53.6%) had metastatic recurrence on PSMA-PET. ROC analysis revealed a cut-off of ≤3 metastatic lesions on PSMA-PET for the steering of treatment decisions towards MDT rather than solely systemic therapy (AUC: 0.88). Defined as 3 or fewer metastatic lesions, oligometastatic recurrent PCa was found in up to 30% (33/110) of all patients. At PSA levels below 3.5 ng/ml, the rate of PSMA-positive disease that was locally confined or oligometastatic was 76% (45/59), dropping significantly to 29.4% (5/17) above this threshold (p<0.001) as polymetastatic findings became more frequent.\u0000\u0000\u0000CONCLUSION\u0000The detection of ≤3 oligometastases on PSMA-PET encouraged the consecutive pursuit of MDT instead of systemic therapy alone. PSMA-PET predominantly captured patients at recurrence stages amenable to localized treatment when initiated at PSA levels below 3.5 ng/ml.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"33 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75606626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Radiation doses from low-dose CT scans in SPECT/CT and PET/CT examinations: A survey in Germany. SPECT/CT和PET/CT低剂量CT扫描的辐射剂量:德国的一项调查。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-04-06 DOI: 10.1055/a-1759-3900

A. Rinscheid, T. Janzen, B. Alikhani, A. Beer, A. Braune, Nina Eberhardt, Diana Fechner, S. Förster, M. Freesmeyer, C. Furth, M. Grunert, D. Hellwig, P. F. Costa, C. Kühnel, C. Lange, R. Linke, N. Razlaw, Tobias Sack, D. Schmidt, Christina Schütze, Alexander Starke, Liane Tondera, H. Wengenmair, K. Zöphel, W. Burchert, C. Lapa

{"title":"Radiation doses from low-dose CT scans in SPECT/CT and PET/CT examinations: A survey in Germany.","authors":"A. Rinscheid, T. Janzen, B. Alikhani, A. Beer, A. Braune, Nina Eberhardt, Diana Fechner, S. Förster, M. Freesmeyer, C. Furth, M. Grunert, D. Hellwig, P. F. Costa, C. Kühnel, C. Lange, R. Linke, N. Razlaw, Tobias Sack, D. Schmidt, Christina Schütze, Alexander Starke, Liane Tondera, H. Wengenmair, K. Zöphel, W. Burchert, C. Lapa","doi":"10.1055/a-1759-3900","DOIUrl":"https://doi.org/10.1055/a-1759-3900","url":null,"abstract":"AIM\u0000Recently, dose reference levels (DRLs) have been defined in Germany for auxiliary low-dose CT scans in hybrid SPECT/CT and PET/CT examinations, based on data from 2016/17. Here, another survey from 2020 was evaluated and compared with the new DRLs as well as with similar surveys from foreign countries.\u0000\u0000\u0000METHODS\u0000The survey, which had already been conducted in the Nordic countries, queried for various examinations including the following values: patient weight and height, volume CT dose index (CTDIvol), dose length product (DLP). For each examination, statistical parameters such as the third quartile (Q3) were determined from all submitted CTDIvol and DLP values. Additionally, for examinations comprising datasets from at least 10 systems, the third quartile (Q3-Med) of the respective median values of each system was calculated. Q3 and Q3-Med were compared with the newly published DRLs from Germany and values from similar studies from other countries.\u0000\u0000\u0000RESULTS\u0000Data from 15 SPECT/CT and 13 PET/CT systems from 15 nuclear medicine departments were collected. For the following examinations datasets from more than 10 systems were submitted: SPECT lung VQ, SPECT bone, SPECT&PET cardiac, PET brain, PET oncology. Especially for examinations of the thorax and heart, the new DRLs are very strict compared to this study. The CTDIvol values for examinations of the head were lower in this study than the DRLs prescribe now.\u0000\u0000\u0000CONCLUSIONS\u0000For certain examination types, there is a need for dose optimization at some clinics and devices in order to take into account the new DRLs in Germany in the future.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"12 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88000316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

[Incorporation Monitoring of Staff using I-131 and Lu-177 in a Nuclear Medicine Ward]. [核医学病房工作人员使用I-131和Lu-177的合并监测]。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-04-06 DOI: 10.1055/a-1759-1940

C. Wanke, Bastian Szemerski, L. Geworski

{"title":"[Incorporation Monitoring of Staff using I-131 and Lu-177 in a Nuclear Medicine Ward].","authors":"C. Wanke, Bastian Szemerski, L. Geworski","doi":"10.1055/a-1759-1940","DOIUrl":"https://doi.org/10.1055/a-1759-1940","url":null,"abstract":"OBJECTIVES\u0000In addition to the well-established therapy with iodine-131, treatments with lutetium-177 are increasingly being performed on an inpatient basis in Germany. All of these treatments have be taken into account when assessing the potential internal dose and for incorporation monitoring of personnel. This article describes the experience with and the results of incorporation monitoring of staff of a nuclear medicine ward of a university hospital in Germany.\u0000\u0000\u0000METHODS\u0000Personnel working in a nuclear medicine ward was regularly measured using a whole body counter. In total, 234 measurements were performed over a period of 12 months. Incorporation factors were determined considering activities handled or applied to patients in the respective time period.\u0000\u0000\u0000RESULTS\u0000In approx. 74 % of measurements, no incorporations was found. In the remaining measurements, activity was detected. Assuming incorporation, the maximum effective dose would be less than 0.15 mSv per measurement. The incorporation factors determined in this work were in the order of magnitude of 10-7 for all groups except for personnel performing radiochemical quality control. For this group, only an upper limit of the incorporation factor of 10-5 can be specified.\u0000\u0000\u0000CONCLUSION\u0000The risk of incorporating radiactivity can be considered low for personnel working in a nuclear medicine ward. An incorporation factor of 10-7 is appropriate for medical, nursing, and cleaning staff and personnel performing radiochemical syntheses.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"17 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79686517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cisplatin - A more Efficient Drug in Combination with Radionuclides? 顺铂-与放射性核素联合使用更有效?

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-04-06 DOI: 10.1055/a-1759-1749

F. Reissig, R. Runge, A. Naumann, J. Kotzerke

{"title":"Cisplatin - A more Efficient Drug in Combination with Radionuclides?","authors":"F. Reissig, R. Runge, A. Naumann, J. Kotzerke","doi":"10.1055/a-1759-1749","DOIUrl":"https://doi.org/10.1055/a-1759-1749","url":null,"abstract":"AIM\u0000The combination of conventional chemotherapeutic drugs with radionuclides or external radiation is discussed for a long period of time. The major advantage of a successful combination therapy is the reduction of severe side effects by decreasing the needed dose and simultaneously increasing therapeutic efficiency.\u0000\u0000\u0000METHODS\u0000In this study, pUC19 plasmid DNA was incubated with the cytostatic drug cisplatin and additionally irradiated with 99mTc, 188Re and 223Ra. To verify the contribution of possibly excited platinum atoms to the emission of Auger electrons we determined DNA damages, such as single- and double strand breaks.\u0000\u0000\u0000RESULTS\u0000The threshold concentration value of cisplatin, which was tolerated by pUC19 plasmid DNA was determined to be 18-24 nM. Nevertheless, even at higher dose values (>100 Gy) and simultaneous incubation of cisplatin to 200 ng plasmid DNA, no significant increase in the number of induced single- and double-strand breaks was obtained, compared to the damage solely caused by the radionuclides.\u0000\u0000\u0000CONCLUSION\u0000We thereby conclude that there is no direct dependence of the mechanism of strand break induction to the absence or presence of platinum atoms attached to the DNA. Reported increasing DNA damages in therapy approaches on a cellular level strongly depend on the study design and are mainly influenced by repair mechanisms in living cells. Nevertheless, the use of radioactive cisplatin, containing the Auger electron emitter 191Pt, 193mPt or 195mPt, is a bright prospect for future therapy by killing tumor cells combining two operating principles: a cytostatic drug and a radiopharmaceutical at the same time.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"15 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90725492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

A Case of Chorea-Acanthocytosis with FDG PET/CT Imaging. 舞蹈病-棘细胞增多症1例FDG PET/CT成像。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-04-06 DOI: 10.1055/a-1780-8463

H. Uslu, Asuman Orhan Varoglu, M. Tatoğlu, Emrah Kılıçaslan

引用次数: 0

[Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios]. [预测Lu-177-PSMA治疗后的出院标准-几种情况的讨论]。

IF 1.5 4区医学

Nuklearmedizin-nuclear Medicine Pub Date : 2022-04-01 Epub Date: 2022-02-15 DOI: 10.1055/a-1697-8126

Wolfgang Tilman Kranert, Benjamin Bockisch, Jennifer Wichert, Daniel Gröner, Amir Sabet, Justus Baumgarten, Linh Quyen Christina Nguyen Ngoc, Frank Grünwald, Christian Happel

{"title":"[Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios].","authors":"Wolfgang Tilman Kranert, Benjamin Bockisch, Jennifer Wichert, Daniel Gröner, Amir Sabet, Justus Baumgarten, Linh Quyen Christina Nguyen Ngoc, Frank Grünwald, Christian Happel","doi":"10.1055/a-1697-8126","DOIUrl":"https://doi.org/10.1055/a-1697-8126","url":null,"abstract":"Aim: The aim is to add a pragmatic contribution to the discussion of an algorithm to discharge patients treated with Lu-177-PSMA under the aspect of radiation protection. This also may be applied to therapies with other radioactive tracers in the future.Material and methods: 478 cycles of Lu-177-PSMA-617 (140 patients) were analyzed. The remaining activity in the patient and the dose rate were correlated. From frequent intratherapeutic measurements (biexponential fit) scenarios for discharging patients are deduced.Results: Thirty-four per cent of all patients treated with Lu-177-PSMA received 3 to 5 cycles per calendar year. The dose limit of 1 mSv per calendar year (German Law) at a distance of 2 m from the patient would be exceeded in 10 % and 15 % of the treated patients if discharged 72 hours after treatment given 3 and 4 cycles per calendar year, respectively. Mean specific dose rate was 0.00462µSv/(h MBq) at a distance of 1 m. A universal correlation between dose rate and the remaining activity in the patient could not be found.Conclusion: The multi cycle concept of the therapies with Lu-177 PSMA has to be taken into account prospectively when discharging the patients. Given the physical half-life of Lu-177 an anticipation of 4 treatment cycles per calendar year leads to a clearly arranged, conservative rule.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 2","pages":"111-119"},"PeriodicalIF":1.5,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39789367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0